New Strategies in Fighting Pancreatic Cancer
With innovative tools and renewed enthusiasm, researchers are focusing on tackling pancreatic cancer, known as one of the most lethal cancers worldwide. They are exploring a radical new approach called cancer interception, which aims to treat abnormal tissues before they can turn malignant and spread.
This interception method is already being tested for other cancers, such as breast and skin cancer. Now, with a promising new drug that has shown success against pancreatic tumors, there’s a growing belief among scientists that this approach could also be effective for pancreatic cancer, which has historically been difficult to treat.
The AACR Conference on Pancreatic Cancer, held recently in San Diego, highlighted cancer interception as a central theme. This meeting was particularly significant as it marked the first gathering since the FDA approved daraxonrasib (Rasonque), a groundbreaking pancreatic cancer drug, back in August. The enthusiasm around this drug has sparked hopes of combining it with emerging therapies and early-detection strategies to fundamentally change how pancreatic cancer is addressed.
Diane Simeone, who leads the Moores Cancer Center at UC San Diego Health, expressed optimism about the combination of early detection methods with interception strategies. She believes such a strategy could dramatically increase the five-year survival rate for pancreatic cancer patients, potentially boosting it from 13.7% to as high as 50%.
It’s an ambitious goal, but the excitement is palpable. Anirban Maitra, director of the Perlmutter Cancer Center at NYU Langone Health, noted that we are now at a point where considering these possibilities is not just hopeful thinking but a real opportunity that wasn’t feasible just a few years ago.
Facing the Challenge of Pancreatic Tumors
Pancreatic tumors are notoriously difficult to deal with. They can be highly invasive and often evade most forms of treatment, wrapping around crucial blood vessels and making them challenging to remove. However, if caught early, survival rates for these tumors can exceed 80%. Unfortunately, symptoms of pancreatic cancer are often vague. Many individuals do not seek medical help promptly, resulting in over half of diagnosis cases occurring after the disease has metastasized. This unfortunate trend hasn’t changed significantly in the last three decades.
To tackle the issue of early detection, Simeone and her team initiated a clinical study called PRECEDE. This study aims to enroll 20,000 participants with a family history of pancreatic cancer or certain precancerous growths. The goal is to find out whether frequent monitoring can enhance survival outcomes. So far, they’ve enrolled about 12,000 individuals, with over 50 diagnosed early enough to take action.
The PRECEDE team also indicates plans to utilize samples from this study to assess the effectiveness of new blood tests designed for early detection. Additionally, they aim to leverage artificial intelligence techniques to identify abnormalities in scans that are not yet visible to human eyes.
Furthermore, there might be an exploration of whether drugs like daraxonrasib can increase survival rates when administered right after surgery to remove precancerous or early-stage tumors. For the moment, this drug is only approved for advanced cancer cases.
Exciting Advances in Research
During the AACR meeting, researchers shared promising findings from studies involving mice. Ben Stanger, a researcher from the University of Pennsylvania, discussed their work with mice that possess mutations in a gene called Kras. These mutations spark the growth of cancer-causing proteins. In their study, when the mice developed pre-cancerous pancreatic growths, they were treated with a drug that, similar to daraxonrasib, inhibits the action of KRAS and associated proteins, resulting in improved survival rates among the mice. Stanger described the findings as incredibly exciting but tempered his enthusiasm with the realization that it could take years to figure out the best ways to apply this technique to human patients.
